Industry: Healthcare | Publish Date: 06-Jul-2024 | No of Pages: 139 | No. of Tables: 104 | No. of Figures: 69 | Format: PDF | Report Code : N/A
The China In-Vitro Diagnostics Market size was valued at USD 12.60 billion in 2023, and is predicted to reach USD 17.24 billion by 2030, at a CAGR of 4.1% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. IVD tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.
These immunodiagnostic tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics. Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.
The prevalence of chronic diseases significantly drives the growth of the in-vitro diagnostics market in China. According to National Institutes of Health, in China, there are higher rates of cardiovascular disease, cancer, chronic respiratory disease, and diabetes compared to regions with similar social development levels.
These non-communicable diseases are responsible for 88.5% of all deaths and contribute to 84.9% of the disease burden, as measured by disability-adjusted life years (DALYs). As these conditions continue to rise, there is an increasing demand for accurate and efficient diagnostic solutions to effectively manage and monitor patient health. IVD tests play a crucial role in this landscape by enabling early disease detection, personalized treatment strategies, and ongoing disease monitoring.
The extensive healthcare infrastructure in the country serves as a pivotal driver for the China in-vitro diagnostics market growth. According to International Trade Administration, with over 36,570 hospitals providing more than 7.4 million beds and catering to 3.88 billion patient visits, China’s healthcare system is well-equipped to handle a vast array of medical needs.
This infrastructure not only facilitates the delivery of healthcare services but also generates a significant demand for diagnostic tests and technologies such as immunodiagnostics. With such widespread accessibility to healthcare facilities and services, there is an increased need for accurate and timely diagnostic solutions to support effective patient management. Consequently, the robust healthcare infrastructure in China fuels the adoption of in-vitro diagnostic technologies, driving the market growth and innovation in the sector.
High costs associated with research, development, and regulatory approval are significant factors restraining the in-vitro diagnostics market expansion. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.
This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.
Point-of-care testing (POCT) is poised to be a significant driver of the growing China IVD market demand in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.
With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.
By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.
The promising players operating in the China in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.
Reagents
Instruments
Software & Services
Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Rapid Tests
Chemiluminescence Immunoassay (CLIA)
Enzyme-linked Immunosorbent spot (ELISpot)
Radioimmunoassay (RIA)
Western Blot
PCR
INAAT
Hybridization
DNA diagnostics
Microarray
Other Molecular Diagnostics
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Renal Profile
Lipid Profile
Thyroid Function Panel
Electrolyte Panel
Speciality Chemicals
Other IVD Techniques
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others
Stand Alone Laboratory
Hospitals
Academics and Medical Schools
Point of Care Testing
Other End Users
REPORT SCOPE AND SEGMENTATION:
Parameters |
Details |
Market Size Value in 2023 |
USD 12.60 billion |
Revenue Forecast in 2030 |
USD 17.24 billion |
Value Growth Rate |
CAGR of 4.1% from 2024 to 2030 |
Analysis Period |
2023–2030 |
Base Year Considered |
2023 |
Forecast Period |
2024–2030 |
Market Size Estimation |
Billion (USD) |
Growth Factors |
|
Companies Profiled |
10 |
Customization Scope |
Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope. |
Pricing and Purchase Options |
Avail customized purchase options to meet your exact research needs. |
Roche Holding AG
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
Bio-Rad Laboratories, Inc.